Osteoporosis and osteosclerosis in sickle cell/β-thalassemia: The role of the RANKL/osteoprotegerin axis

Haematologica

Volumn 91, Issue 6, 2006, Pages 813-816

  Voskaridou, Ersi ^a   Stoupa, Eleni ^b   Antoniadou, Lito ^c   Premetis, Evangelos ^d   Konstantopoulos, Kostas ^e   Papassotiriou, Ioannis ^d   Terpos, Evangelos ^b  

^a LAIKO GENERAL HOSPITAL   (Greece)

^b General Airforce Hospital   (Greece)

^c BIOIATRIKI HEALTHCARE GROUP   (Greece)

^d AGHIA SOPHIA CHILDREN S HOSPITAL   (Greece)

^e UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Bone mineral density; Osteoporosis; Osteosclerosis; Sickle cell disease; Thalassemia

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

ADULT; AGED; ARTICLE; BETA THALASSEMIA; BONE DENSITY; CELL ACTIVITY; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; OSTEOCLAST; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; OSTEOSCLEROSIS; SICKLE CELL;

ADULT; AGED; ANEMIA, SICKLE CELL; BETA-THALASSEMIA; BONE DENSITY; BONE REMODELING; CARRIER PROTEINS; FEMALE; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; OSTEOPOROSIS; OSTEOSCLEROSIS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B;

EID: 33745753713     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Almeida A, Roberts I. Bone involvement in sickle cell disease. Br J Haematol 2005;129:482-90.
2. Murray RO. Radiology of sickle cell disease. Proc R Soc Med 1974;67:1071-2.
3. Brinker MR, Thomas KA, Meyers SJ, Texada T, Humbert JR, Cook SD, et al. Bone mineral density of the lumbar spine and proximal femur is decreased in children with sickle cell anemia. Am J Orthop 1998;27:43-9.
4. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymphnode organogenesis. Nature 1999;397:315-23.
5. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-19.
6. Yano K, Tsuda E, Washida N, Kobayashi F, Goto M, Harada A, et al. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in post-menopausal women with osteoporosis. J Bone Miner Res 1999;14:518-27.
7. Voskaridou E, Terpos E, Spina G, Palermos J, Rahemtulla A, Loutradi A, et al. Pamidronate is an effective treatment for osteoporosis in patients with β-thalassaemia. Br J Haematol 2003;123:730-7.
8. Morabito N, Gaudio A, Lasco A, Atteritano M, Pizzoleo MA, Cincotta M, et al. Osteoprotegerin and RANKL in the pathogenesis of thalassemia-induced osteoporosis: new pieces of the puzzle. J Bone Miner Res 2004;19:722-7.
9. Terpos E, Mihou D, Szydlo R, Tsimirika K, Karkantaris C, Politou M, et al. The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio. Leukemia 2005;19:1969-76.
10. Voskaridou E, Terpos E, Michail S, Hantzi E, Anagnostopoulos A, Margeli A, et al. Early markers of renal dysfunction in patients with sickle cell/beta-thalassemia. Kidney Int 2006; in press.
11. Mezquita-Raya P, de la Higuera M, Garcia DF, Alonso G, Ruiz-Requena ME, de Dios Luna J, et al. The contribution of serum osteoprotegerin to bone mass and vertebral fractures in post-menopausal women. Osteoporos Int 2005;16:1368-74.
12. Schett G, Kiechl S, Redlich K, Oberhollenzer F, Weger S, Egger G, et al. Soluble RANKL and risk of nontraumatic fracture. JAMA 2004;291:1108-13.
13. Langub MC Jr, Koszewski NJ, Turner HV, Monier-Faugere MC, Geng Z, Malluche HH. Bone resorption and mRNA expression of 1L-6 and IL-6 receptor in patients with renal osteodystrophy. Kidney Int 1996;50:515-20.
14. Miller PD. Treatment of osteoporosis in chronic kidney disease and end-stage renal disease. Curr Osteoporos Rep 2005;3:5-12.
15. Usui Y, Kawai K, Hirohata K. An electron microscopic study of the changes observed in osteocytes under ischemic conditions. J Orthop Res 1989;7:12-21.
16. Fiore CE, Riccobene S, Mangiafico R, Santoro F, Pennisi P. Hepatitis C-associated osteosclerosis (HCAO): report of a new case with involvement of the OPG/RANKL system. Osteoporos Int 2005;16:2180-4.
17. Manganelli P, Giuliani N, Fietta P, Mancini C, Lazzaretti M, Pollini A, et al. OPG/RANKL system imbalance in a case of hepatitis C-associated osteosclerosis: the pathogenetic key? Clin Rheumatol 2005;24:296-300.